A MULTI-CENTRE PHASE III STUDY TO EVALUATE PRE-EMPTIVE TENOFOVIR FOR PREVENTION OF HEPATITIS B VIRUS REACTIVATION IN HBSAG NEGATIVE/ANTI-HBC POSITIVE INDIVIDUALS UNDERGOING RITUXIMAB-BASED CHEMOTHERAPY FOR NON-HODGKIN'S LYMPHOMA/SMALL LYMPHOCYTIC LEUKEMIA.
- Registry ID
- JF62014
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- UNIVERSITY HEALTH NETWORK
- Start date
- 2015-05-21
- Last update
- 2014-08-11
Conditions
- HEPATITIS B VIRUS
- NON-HODGKIN LYMPHOMA
Related clinical trials
- A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-1045 MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH NON-HODGKIN LYMPHOMA
- AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
- A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED MULTICENTER PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF ALG-000184 COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE IN UNTREATED HBEAG-POSITIVE AND HBEAG-NEGATIVE ADULT SUBJECTS WITH CHRONIC HEPATITIS B VIRUS INFECTION (B-SUPREME)
- A PHASE 1 TRIAL OF BTM-3566 IN RELAPSED/REFRACTORY MATURE B CELL LYMPHOMAS AND ADVANCED SOLID TUMORS
- A PHASE 2B, MULTI-CENTRE, RANDOMIZED, PARTIALLY PLACEBO-CONTROLLED, DOUBLE-BLIND
STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SEQUENTIAL THERAPY WITH
DAPLUSIRAN/TOMLIGISIRAN FOLLOWED BY BEPIROVIRSEN IN PARTICIPANTS WITH CHRONIC
HEPATITIS B VIRUS ON BACKGROUND NUCLEOS(T)IDE ANALOGUE THERAPY (B-UNITED)
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO ASSESS THE
EFFICACY AND SAFETY OF TREATMENT WITH BEPIROVIRSEN IN PARTICIPANTS LIVING WITH
HUMAN IMMUNODEFICIENCY VIRUS AND CHRONIC HEPATITIS B VIRUS INFECTION ON
ANTIRETROVIRAL TREATMENT
View on source registry